Sanofi, MannKind accord licensing deal for Afrezza insulin

August 11, 2014 7:38 AM

20 0

Adult insulin dependent Americans will get a new cure, Afrezza insulin therapy, from the French manufacturer Sanofi and MannKind corporation. The licensing deal means that manufacturer will elaborate and put on sale Afrezza inhalated insulin therapy for diabetics.

Inhalated therapy can completely or partly replace the insuline injections and is a great scientific breakthrough in the battle against diabet. Affeza is planned to be launched in America at the begginning of 2015.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page